RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 2975-2981

  Buhmeida, Abdelbaset ^a   Merdad, Adnan ^a   El Maghrabi, Joudah ^a   Al Thobaiti, Fatima ^a   Ata, Manar ^a   Bugis, Ayman ^a   Syrjänen, Kari ^b   Abuzenadah, Adel ^a   Chaudhary, Adeel ^a   Gari, Mamdooh ^a   Al Qahtani, Mohammed ^a   Dallol, Ashraf ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Breast cancer; Methylation; Prognosis; RASSF1A

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; ESTROGEN RECEPTOR ALPHA; HYPERMETHYLATED IN CANCER 1; PROGESTERONE RECEPTOR; RETINOIC ACID RECEPTOR BETA; SECRETED FRIZZLED RELATED PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MYOGENIC DIFFERENTIATION 1 GENE; PAIRED LIKE HOMEODOMAIN 2 GENE; PRIORITY JOURNAL; PROGNOSIS; RAS ASSOCIATION DOMAIN FAMILY MEMBER 1 ISOFORM A GENE; SLIT HOMOLOG 2 GENE; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BREAST NEOPLASMS; COHORT STUDIES; DNA METHYLATION; DNA PRIMERS; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 80051629941     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. IARC Cancer Mondial. http://wwwdep.iarc.fr/ Lyon. World Health Organisation, 2009.
2. El Saghir NS, Khalil MK, Eid, T El Kinge AR, Charafeddine M, Geara F, Seoud M and Shamseddine AI: Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg 5: 225-233, 2007. (Pubitemid 47095487)
3. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D, Li LC, Tabatabai ZL, Kawahara M, Nakagawa M, Kane CJ, Carroll PR and Dahiya R: Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer 116: 174-181, 2005. (Pubitemid 40967252)
4. Lee JS, Lo PK, Fackler MJ, Argani P, Zhang Z, Garrett-Meyer E and Sukumar SA: comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women. Cancer Biol Ther 6: 1114-1120, 2007. (Pubitemid 351574965)
5. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G and Widschwendter M: Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 65: 1141-1145, 2005. (Pubitemid 40270136)
6. Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grutzmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Muller V, Milde-Langosch K, Nahrig J, Foekens J, Maier S, Schmitt M and Lesche R: Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 26: 5036-5042, 2008.
7. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, Stegmaier C, Jacobs IJ and Brenner H: Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One 3: e2656, 2008.
8. Dallol A, Al-Ali W, Al-Shaibani A and Al-Mulla F: Analysis of DNA methylation in FFPE tissues using the MethyLight technology. Methods Mol Biol 724: 191-204, 2011.
9. Hawes SE, Stern JE, Feng Q, Wiens LW, Rasey JS, Lu H, Kiviat NB and Vesselle H: DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. Lung Cancer 69: 172-179, 2010.
10. Su PF, Huang WL, Wu HT, Wu CH, Liu TY and Kao SY: p16(INK4A) promoter hypermethylation is associated with invasiveness and prognosis of oral squamous cell carcinoma in an age-dependent manner. Oral Oncol 46: 734-739, 2010.
11. Berner C, Aumuller E, Gnauck A, Nestelberger M, Just A and Haslberger AG: Epigenetic control of estrogen receptor expression and tumor suppressor genes is modulated by bioactive food compounds. Ann Nutr Metab 57: 183-189, 2010.
12. INK4a. EMBO Mol Med 2: 458-471, 2010.
13. Ongenaert M, Van Neste L, De Meyer T, Menschaert G, Bekaert, S and Van Criekinge W: PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res 36: D842-846, 2008.
14. Fourkala EO, Hauser-Kronberger C, Apostolidou S, Burnell M, Jones A, Grall J, Reitsamer R, Fiegl H, Jacobs I, Menon U and Widschwendter M: DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery. Breast Cancer Res Treat 120: 345-355, 2010.
15. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP, Savage DA, Mueller-Holzner E, Marth C, Kocjan G, Gayther SA, Jones A, Beck S, Wagner W, Laird, PW, Jacobs IJ and Widschwendter M: Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 20: 440-446, 2010.
16. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA and Laird PW: Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64: 3807-3813, 2004. (Pubitemid 38697289)
17. Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V and Lianidou ES: Prognostic significance of RASSF1A promoter methylation in operable breast cancer. Clin Biochem 42: 970-975, 2009.
18. Martins AT, Monteiro P, Ramalho-Carvalho J, Costa VL, Dinis-Ribeiro M, Leal C, Henrique R and Jeronimo C: High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. Breast Cancer Res Treat, 2010.